Synergy CRO

srgcro.com

Since 2002, SRG provides support to the pharmaceutical, biotechnology and medical device industries with a comprehensive range of collaborative services and solutions. In order to help our clients meet their clinical research goals we constantly explore and implement new ways to evolve the drug development process as well as look for cost-effective solutions. Through this work, we have come to value and respect up to date technologies along with time-tested traditional solutions. Loyalty to traditions, Openness to innovation With its unique philosophic mindset, Synergy is now the leading full-service contract research organization (CRO).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

news image

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More

Research

IDBS LAUNCHES POLAR™ IN A NEW PRODUCT CATEGORY THAT AIMS TO STREAMLINE AND SPEED UP BIOPHARMACEUTICAL DEVELOPMENT

IDBS | December 07, 2020

news image

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that with...

Read More

Business Insights

ERT EXPANDS CLINICAL IMAGING REPORTING CAPABILITIES IN ITS BUSINESS INTELLIGENCE SUITE

ERT | April 16, 2021

news image

ERT, the worldwide pioneer in clinical endpoint data collection, today declared that its demonstrated Business Intelligence suite has extended to incorporate detailing for clinical preliminary imaging, making study data all the more effectively available and noteworthy. The new imaging capabilities give an elevated degree of data that empowers study pioneers to guarantee consummation, and successfully oversee locales, expenses, and profitability. "Imaging studies are complex,...

Read More
news image

Research

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More
news image

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More
news image

Research

IDBS LAUNCHES POLAR™ IN A NEW PRODUCT CATEGORY THAT AIMS TO STREAMLINE AND SPEED UP BIOPHARMACEUTICAL DEVELOPMENT

IDBS | December 07, 2020

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that with...

Read More
news image

Business Insights

ERT EXPANDS CLINICAL IMAGING REPORTING CAPABILITIES IN ITS BUSINESS INTELLIGENCE SUITE

ERT | April 16, 2021

ERT, the worldwide pioneer in clinical endpoint data collection, today declared that its demonstrated Business Intelligence suite has extended to incorporate detailing for clinical preliminary imaging, making study data all the more effectively available and noteworthy. The new imaging capabilities give an elevated degree of data that empowers study pioneers to guarantee consummation, and successfully oversee locales, expenses, and profitability. "Imaging studies are complex,...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us